Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT04973384
Active, not recruiting Observational

Ocular Comorbidity in Atopic Dermatitis

NCT04973384 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital, Rigshospitalet
Phase
Observational
Started
2021-08-05
Last updated
2024-11-15

Condition(s) studied

Atopic Keratoconjunctivitis

Study summary

A clinical characterization of a large cohort of patients with different severities of AD and ocular symptoms/atopic keratoconjunktivitis (AKC). The data will contribute to assess the frequency of complications in order to give a rationale for focused prevention and treatment strategy.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Danish talking * Diagnosed with atopic dermatitis (AD) * Current or previous ocular symptoms suspected to be atopic keratoconjunctivitis Exclusion Criteria: * No pause in eyedrops * Ocular infections within the last 3 months * Use of local or systemic antibiotics within the last 3 months * Significant untreated systemic disease such as hypertension, heart failure, diabetes mellitus, previous cerebral infarction or bleeding, lung diseases and autoimmune diseases other than atopic dermatitis and related comorbidities. The diseases are accepted if they are well treated or do not require treatment * Current pregnant or breastfeeding * Use of contact lenses, unless these are paused 2 weeks before the examination or they are due to keratoconus treatment * If the eye symptoms turn out not to be related to atopic keratoconjunctivitis * If it is assessed that the individual cannot participate sufficiently for the examination

Primary outcome measure(s)

  • Bulbar redness (BR) score — 1 day At examination
    Difference in Bulbar redness (BR) score (Keratograph 5M, R-scan). Scale from 0-4. A higher score indicates more severe BR.

Trial sites (1)

FacilityCityRegionStatus
Department of Ophthalmology, Rigshospitalet-Glostrup Glostrup Municipality Denmark

More Copenhagen University Hospital, Rigshospitalet trials in Denmark

Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria Recruiting
Immediate Versus Postponed Single Blastocyst Transfer in mNC-FET Active, not recruiting
The Copenhagen Gender Identity Cohort Recruiting
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection Recruiting
Precision Medicine in the Depression Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04973384 on ClinicalTrials.gov ↗ ← All trials in Denmark